鶹ýӰ

Meeting Coverage

NANETS

North American Neuroendocrine Tumor Society

SSA Transition Safe, Effective for NETs

Long-term survival, cost-effectiveness examined in other studies

image

Latest NANETS Meeting Coverage

Surveillance Appears Reasonable for Small pNETs

All patients with tumors <1 cm alive at 5 years without surgery

October 8, 2018
Surgery Improves Survival for most pNETs

Mortality odds 70%-80% lower for all but stage I disease

October 6, 2018
Salvage Tx with Radioactive Octreotate Effective for Neuroendocrine Tumors

Overall survival lengthened with salvage therapy

October 23, 2017
92-Gene Assay: Promising for Molecular NET Classification

Identifies seven NET subtypes for those with uncertain diagnoses

October 22, 2017
Radionuclide Tx Boosts QoL in Patients with Midgut NETs

177Lu-dotatate provides significant benefit for global health status and more

October 22, 2017
Good Outcomes with Cabozantinib in Carcinoid, PNET Tumors

Treatment associated with objective tumor responses, encouraging PFS

October 22, 2017